リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Treatment Outcomes in Patients with Atypical EGFR-positive Non-small Cell Lung Cancer in Nagano Prefecture, Japan」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Treatment Outcomes in Patients with Atypical EGFR-positive Non-small Cell Lung Cancer in Nagano Prefecture, Japan

Agatsuma, Toshihiko Kanda, Shintaro Yamamoto, Ryouhei Ono, Yasushi Nishie, Kenichi Tanaka, Hozumi Matsuo, Akemi Shibutani, Mio Koizumi, Tomonobu 信州大学

2022.12.15

概要

Background : This study was performed to evaluate clinical practices in patients with atypical epidermal growth factor receptor (EGFR)-positive inoperable non-small cell lung cancer (NSCLC) in Nagano Prefecture, Japan.

Patients and methods : Patients with newly diagnosed atypical EGFR-positive inoperable NSCLC in 14 hospitals in Nagano, Japan, between May 2016 and March 2019 were enrolled in this study. Atypical EGFR mutations included G719X, S768I, L861Q, compound mutations, and coexistence of de novo T790N in this study. After registering baseline clinical characteristics and initial treatment, serial data were recorded every 4 months in each patient. Initial and serial therapies were at the discretion of the attending physician.

Results : The study population consisted of 24 patients with atypical EGFR-positive NSCLC (12 men and 12 women ; median age : 78.5 years ; range : 49-89 years). Fourteen patients had single G719X, S768I, or L861Q mutation and 10 had compound EGFR mutations. Performance statuses 0/1/2/3/4 were seen in 11/7/3/2/1 cases and clinical stage I/II/III/IV/ recurrence occurred in 1/0/0/15/8 cases, respectively. One patient with clinical stage IA was treated with radiotherapy. Other patients were treated with EGFR-tyrosine kinase inhibitors (TKIs) as first (n＝21) or second (n＝2)-line therapy, and the response rate to TKIs was 56.5 ％. Median overall survival was 23.9 months (95 ％ confidence interval ［CI］: 10.2 months to NA) in atypical EGFR-positive cases.

Conclusion : The present results reveal that clinical outcomes in patients with atypical EGFR- positive NSCLCs in Nagano prefecture were comparable with those in other clinical trials and studies. Shinshu Med J 70 : 397― 405, 2022

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1）　Siegel RL, Miller KD, Fuchs HE, Jemal A : Cancer Statistics, 2021. CA Cancer J Clin 71 : 7-33, 2021

2）　National Cancer Registry (Ministry of Health, Labour and Welfare), tabulated by Cancer Information Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html

3）　Cancer Statistics in Japan 2021. https://ganjoho.jp/public/qa_links/report/statistics/2021_en.html

4）　Okamoto I, Morita S, Tashiro N, et al : Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer : Long-term follow-up of a large patient cohort. Lung Cancer 117 : 14-19, 2018

5）　Sonehara K, Kobayashi T, Tateishi K, et al : Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib -A Nagano Lung Cancer Research Group- Thorac Cancer 10 : 1078-1085, 2019

6）　Mok TS, Wu Y-L, Ahn M-J, et al : Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376 : 629-640, 2017

7）　Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al : Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378 : 113-125, 2018

8）　Mitsudomi T, Morita S, Yatabe Y, et al : Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol 11 : 121-128, 2010

9）　Evans M, O’Sullivan B, Smith M, et al : Large-Scale EGFR Mutation Testing in Clinical Practice : Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases. Pathol Oncol Res 25 : 1401-1409, 2019

10）　Si J, Gu X, Wang W, Ying S, Song Z : Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs). Ann Palliat Med 11 : 1624-1634, 2022

11）　Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC : Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17 : 3812-3821, 2011

12）　Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, et al : Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16 : 830-838, 2015

13）　Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, et al : Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations : a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 38 : 488-495, 2020

14）　Kobayashi T, Kanda S,Tateishi K, et al : Multi-institutional cohort study of patients with EGFR-and ALK positive non-small-cell lung cancer in Nagano prefecture, Japan. (submission).

15）　Kim EY, Cho EN, Park HS, et al : Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 17 : 237-245, 2016

16）　Kohsaka S, Nagano M, Ueno T, et al : A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med 9 : eaan6566, 2017

17）　Yu HA, Arcila ME, Rekhtman N, et al : Analysis of tumor specimens at the time of acquired resistance to EGFRTKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19 : 2240-2247, 2013

18）　Li W, Qiu T, Guo L, Ling Y, Gao Y, Ying J, He J : Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Lett 423 : 9-15, 2018

19）　Chiu CH, Yang CT, Shih JY, et al : Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/ L861Q/S768I mutations. J Thorac Oncol 10 : 793-799, 2015

20）　Ikemura S, Yasuda H, Matsumoto S, et al : Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A 116 : 10025-10030, 2019

21）　Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al : Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting : A hospital-based study. Cancer Sci 110 : 1480-1490, 2019

22）　Onozawa H, Saito H, Sunami K, et al : Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test : Negative diagnosis on initial companion test and successful treatment with osimertinib. Thorac Cancer 11 : 3599-3604, 2020

23）　Chang JW, Huang CY, Fang YF, et al : Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation : A retrospective study of 44 patients. Thorac Cancer 13 : 1888-1897, 2022

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る